With a market capitalization (market cap) of $1.97B — a measure of how much the company is worth — Aurinia Pharmaceuticals Inc. is the 2121st most valuable company in Healthcare as of August 18, 2026. Shares trade at $15.30, up +0.07% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Visit websiteAs of August 18, 2026, Aurinia Pharmaceuticals Inc. (AUPH) is worth $1.97B — this is its market capitalization, the total value of all its outstanding shares.
Aurinia Pharmaceuticals Inc.’s market cap is $1.97B, which ranks it #2121 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Aurinia Pharmaceuticals Inc. (AUPH) shares trade at $15.30, up 0.07% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Aurinia Pharmaceuticals Inc. trades at a price-to-earnings (P/E) ratio of 7.1, based on its latest share price and annual earnings per share.